A 6-year-old boy from rural India presents with 3 weeks of fever, bone pain, and hepatosplenomegaly. CBC shows Hb 8.5 g/dL, WBC 120,000/µL with 70% blasts, platelets 45,000/µL. Flow cytometry confirms B-cell ALL. Uric acid is 9.2 mg/dL, creatinine 1.8 mg/dL (age-adjusted upper limit 0.8), LDH 2400 U/L. What is the most appropriate immediate management before starting chemotherapy?

Question

Accepted Answer

A. Give rasburicase 0.2 mg/kg IV, hydrate, and monitor; start chemotherapy once uric acid <7 mg/dL and creatinine improves. ## Clinical Context This child has **high-risk B-ALL with tumor lysis syndrome (TLS) risk** — evidenced by: - Very high WBC (120,000/µL) - Elevated uric acid (9.2 mg/dL, normal <5.5) - Acute kidney injury (creatinine 1.8, age-adjusted ULN 0.8) - Elevated LDH (2400 U/L, indicates high tumor burden) ## Why Rasburicase Is Superior to Allopurinol **High-Yield:** In acute leukemia with high tumor burden and renal dysfunction, **rasburicase is the preferred urate-lowering agent**. | Feature | Rasburicase | Allopurinol | |---------|-------------|-------------| | **Mechanism** | Uricase enzyme; converts uric acid → allantoin (inactive) | Xanthine oxidase inhibitor; reduces uric acid production | | **Onset** | Rapid (within 30 min–4 hrs) | Slow (24–48 hrs) | | **Efficacy in TLS** | Superior; reduces uric acid by 90% | Moderate; takes days to be effective | | **Renal dysfunction** | Safe; works even in AKI | Contraindicated in severe renal failure (risk of xanthine precipitation) | | **Cost** | Higher | Lower | | **Use in India** | Available in tertiary centers | Widely used but slower | **Key Point:** Allopurinol is contraindicated or ineffective in acute kidney injury because it cannot prevent the acute surge of uric acid from tumor lysis, and it increases xanthine levels (which can precipitate in renal tubules). ## Correct Management Sequence 1. **Rasburicase 0.2 mg/kg IV** — rapidly converts existing uric acid to allantoin 2. **Aggressive IV hydration** — promotes urine output and flushes uric acid 3. **Monitor uric acid, creatinine, potassium, phosphate hourly** — detect worsening TLS 4. **Start chemotherapy only after uric acid normalizes** (<7 mg/dL) and creatinine begins to improve **Clinical Pearl:** In India, rasburicase availability may be limited in rural centers. If unavailable, allopurinol + hydration + frequent monitoring is the alternative, but rasburicase is the gold standard. ## Why Immediate Chemotherapy Is Dangerous Starting chemotherapy before controlling uric acid will cause: - Massive tumor lysis → hyperuricemia, hyperkalemia, hyperphosphatemia - Acute kidney injury progression - Cardiac arrhythmias (from K^+^ and phosphate) - Seizures (from hypocalcemia secondary to hyperphosphatemia) - Death ## Management Algorithm ```mermaid flowchart TD A[High-risk ALL suspected]:::outcome --> B{Assess TLS risk:
WBC, LDH, uric acid,
creatinine}:::decision B -->|High risk:
WBC >100K, uric acid >8,
AKI present| C[Rasburicase 0.2 mg/kg IV]:::action C --> D[IV hydration 3 L/m²/day]:::action D --> E[Monitor uric acid, K, PO4,
creatinine q1h]:::action E --> F{Uric acid normalized
& creatinine improving?}:::decision F -->|Yes| G[Start induction chemotherapy]:::action F -->|No| H[Continue hydration & monitoring]:::action H --> F G --> I[Continue TLS prophylaxis
during induction]:::action ``` ![Acute Leukemias diagram](https://mmcphlazjonnzmdysowq.supabase.co/storage/v1/object/public/blog-images/explanation/2637.webp)

Answer

B. Start allopurinol 10 mg/kg/day and begin induction chemotherapy within 24 hours

Answer

C. Initiate IV hydration (3 L/m²/day), allopurinol, and monitor uric acid and creatinine; start chemotherapy only after uric acid normalizes

Answer

D. Perform urgent hemodialysis, then start chemotherapy immediately

Explanation

Clinical Context

Why Rasburicase Is Superior to Allopurinol

Correct Management Sequence

Why Immediate Chemotherapy Is Dangerous

Management Algorithm

Practice similar questions

Join our NEET PG community

Feature	Rasburicase	Allopurinol
Mechanism	Uricase enzyme; converts uric acid → allantoin (inactive)	Xanthine oxidase inhibitor; reduces uric acid production
Onset	Rapid (within 30 min–4 hrs)	Slow (24–48 hrs)
Efficacy in TLS	Superior; reduces uric acid by 90%	Moderate; takes days to be effective
Renal dysfunction	Safe; works even in AKI	Contraindicated in severe renal failure (risk of xanthine precipitation)
Cost	Higher	Lower
Use in India	Available in tertiary centers	Widely used but slower